It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lymph nodes (LNs) and distant metastases can arise from independent subclones of the primary tumor. Herein, we characterized the molecular landscape and the differences between LNs, distant metastases and primary colorectal cancers (CRCs). Samples were analyzed using next generation sequencing (NGS, MiSeq on 47 genes, NextSeq on 592 genes) and immunohistochemistry. Tumor mutational burden (TMB) was calculated based on somatic nonsynonymous missense mutations, and microsatellite instability (MSI) was evaluated by NGS of known MSI loci. In total, 11,871 samples were examined, comprising primaries (N = 5862), distant (N = 5605) and LNs metastases (N = 404). The most frequently mutated genes in LNs were TP53 (72%), APC (61%), KRAS (39%), ARID1A (20%), PIK3CA (12%). LNs showed a higher mean TMB (13 mut/MB) vs distant metastases (9 mut/MB, p < 0.0001). TMB-high (≥17mut/MB) and MSI-H (8.8% and 6.9% vs 3.7%, p < 0.001 and p = 0.017, respectively) classifications were more frequent in primaries and LNs vs distant metastases (9.5% and 8.8% vs 4.2%, p < 0.001 and p = 0.001, respectively). TMB-high is significantly more common in LNs vs distant metastases and primaries (P < 0.0001), regardless MSI-H status. Overall, LNs showed significantly different rates of mutations in APC, KRAS, PI3KCA, KDM6A, and BRIP1 (p < 0.01) vs primaries, while presenting a distinct molecular profile compared to distant metastases. Our cohort of 30 paired samples confirmed the molecular heterogeneity between primaries, LNs, and distant metastases. Our data support the hypothesis that lymphatic and distant metastases harbor different mutational landscape. Our findings are hypothesis generating and need to be examined in prospective studies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); University of Genoa, Medical Oncology Unit 1, Ospedale Policlinico San Martino, Genoa, Italy (GRID:grid.42505.36)
2 Medical University of Innsbruck, Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Innsbruck, Austria (GRID:grid.5361.1) (ISNI:0000 0000 8853 2677)
3 Caris Life Sciences, Phoenix, USA (GRID:grid.492659.5) (ISNI:0000 0004 0492 4462)
4 West Virginia University Cancer Institute, Morgantown, USA (GRID:grid.268154.c) (ISNI:0000 0001 2156 6140)
5 University of Genoa, Medical Oncology Unit 1, Ospedale Policlinico San Martino, Genoa, Italy (GRID:grid.268154.c)
6 University of Tennessee, West Cancer Center, Germantown, USA (GRID:grid.411461.7) (ISNI:0000 0001 2315 1184)
7 Wayne State University, Department of Oncology, Karmanos Cancer Institute, Detroit, USA (GRID:grid.254444.7) (ISNI:0000 0001 1456 7807)
8 Carolinas HealthCare System, Levine Cancer Institute, Charlotte, USA (GRID:grid.427669.8) (ISNI:0000 0004 0387 0597)
9 University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
10 Brown University and Lifespan Cancer Institute (LCI), Providence, USA (GRID:grid.40263.33) (ISNI:0000 0004 1936 9094)
11 Mays Cancer Center, UT Health San Antonio San Antonio, San Antonio, USA (GRID:grid.42505.36)
12 The University of South Alabama, Mitchell Cancer Institute, Mobile, USA (GRID:grid.267153.4) (ISNI:0000 0000 9552 1255)
13 Fox Chase Cancer Center, Medical Oncology and Population Sciences, Phoenix, USA (GRID:grid.249335.a) (ISNI:0000 0001 2218 7820)
14 Georgetown University Medical Center, Ruesch Center for The Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438)